Stocksigma LogoStocksigma Logo

Symbiotec Subsidiary Signs U.S. Commercialization Deal for Injectable Products

Symbiotec Pharmalab鈥檚 wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive agreement with a leading global pharmaceutical company on

Symbiotec Subsidiary Signs U.S. Commercialization Deal for Injectable Products

Symbiotec Pharmalab Ltd 路 Others (Uncategorized) 路 01 Oct 2026, 1:39 am

Symbiotec Subsidiary Signs U.S. Commercialization Deal for Injectable Products Symbiotec Pharmalab鈥檚 wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive agreement with a leading global pharmaceutical company on 30th Sep'26. The partner gains exclusive rights to commercialize and distribute two Dual Chamber Vial (DCV) injectable products in the U.S., targeting an addressable market estimated at ~$288 million. Knovea will manage development, regulatory filings, manufacturing, and supply. In return, Knovea will receive development, regulatory, and commercial milestone payments, alongside ongoing post-launch profit-sharing.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements